Corvus Pharmaceuticals, Inc. (CRVS) Tops Q1 EPS by 5c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q1 EPS of ($0.17), $0.05 better than the analyst estimate of ($0.22).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Benchmark Reiterates Buy Rating on Malibu Boats (MBUU) on Significant Earnings Upside
• Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial